SAN DIEGO & EMERYVILLE, Calif. – Family Eye Care Optometry and NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announced that Guru Sharma O.D. Ph.D., Optometrist at Family Eye Care Optometry and Assistant Professor at Western University of the Health Sciences’ College of Optometry, presented new research documenting the successful use of Avenova™ on patients with blepharitis during the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).
Dr. Sharma’s poster presentation was held today, May 6, from 11:00 a.m.–12:45 p.m. in the Exhibit Hall of the Colorado Convention Center. His study followed 18 patients with mild to moderate blepharitis who were treated twice daily for two weeks with NovaBay’s Avenova (formerly known as i-Lid Cleanser).
“The results were very encouraging,” said Dr. Sharma. “One hundred percent of the study patients with mild blepharitis showed improvement both in objective symptoms, such as redness and swelling, and in subjective symptoms, like discomfort and itching. This study indicates that Avenova could offer significant benefits in the management of blepharitis, an eye condition suffered by millions of Americans. It has the added advantage of being easy and safe to use which allows high compliance rate and patient’s satisfaction.”
Avenova is the only lid & lash cleanser to contain Neutrox. Neutrox is NovaBay’s proprietary pure hypochlorous acid, which mimics a naturally occurring substance produced by white blood cells to fight microbial invaders. Lab tests show that NovaBay’s proprietary formulation of hypochlorous acid is effective in solution both at killing microbes and at neutralizing the bacterial enzymes and toxins that contribute to common eye conditions like blepharitis and meibomian gland dysfunction.
“Dr. Sharma’s study offers scientific confirmation of what many doctors have already reported in their own practices—that Avenova represents an important advancement in the management of the common chronic eye condition blepharitis,” said Ron Najafi, Ph.D., President and CEO of NovaBay, a biopharmaceutical company commercializing and developing non-antibiotic antimicrobial products for the global eye care market.
Avenova* is the only eye care product to contain Neutrox™, NovaBay’s proprietary, pure hypochlorous acid (HOCl) with all the bleach (sodium hypochlorite) impurities removed. HOCl is a naturally occurring substance produced by white blood cells to fight microbial invaders. Laboratory tests show it has potent antimicrobial activity in solution and yet is non-toxic to normal healthy human cells. Neutrox also neutralizes bacterial toxins in vitro. Avenova is uniquely suited for daily use by the millions of Americans who suffer from chronic eye conditions like blepharitis and dry eye. It is the only such product designed for continuous daily eyelid hygiene.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by the FDA, and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North Africa and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).
This news release contains “forward-looking statements.” These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, commercial potential and financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” NovaBay undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For NovaBay Avenova purchasing information, please contact:
Toll Free: 1-800-890-0329
At the Company
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson